The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
 

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response yesterday released resources focused on…
Headline
The Federal Emergency Management Agency this month issued COVID-19 pandemic operational guidance for the forthcoming hurricane season. Included in the document…
Headline
The Committee on Ways and Means today convened a hearing examining the disproportionate effect COVID-19 is having on minority communities. “Many communities…
Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…